Literature DB >> 8809464

Immunopathogenesis of recurrent vulvovaginal candidiasis.

P L Fidel1, J D Sobel.   

Abstract

Recurrent vulvovaginal candidiasis (RVVC) is a prevalent opportunistic mucosal infection, caused predominantly by Candida albicans, which affects a significant number of otherwise healthy women of childbearing age. Since there are no known exogenous predisposing factors to explain the incidence of symptomatic vaginitis in most women with idiopathic RVVC, it has been postulated that these particular women suffer from an immunological abnormality that prediposes them to RVVC. Because of the increased incidence of mucosal candidiasis in individuals with depressed cell-mediated immunity (CMI), defects in CMI are viewed as a possible explanation for RVVC. In this review, we attempt to place into perspective the accumulated information regarding the immunopathogenesis of RVVC, as well as to provide new immunological perspectives and hypotheses regarding potential immunological deficiencies that may predispose to RVVC and potentially other mucosal infections by the same organism. The results of both clinical studies and studies in an animal model of experimental vaginitis suggest that systemic CMI may not be the predominant host defense mechanism against C. albicans vaginal infections. Rather, locally acquired mucosal immunity, distinct from that in the peripheral circulation, is now under consideration as an important host defense at the vaginal mucosa, as well as the notion that changes in local CMI mechanism(s) may predispose to RVVC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809464      PMCID: PMC172897          DOI: 10.1128/CMR.9.3.335

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  104 in total

1.  Lymphoid tissue of the normal fallopian tube--a form of mucosal-associated lymphoid tissue (MALT)?

Authors:  H Morris; M Emms; T Visser; A Timme
Journal:  Int J Gynecol Pathol       Date:  1986       Impact factor: 2.762

2.  Immunoblot analysis of the serological response in systemic candidosis.

Authors:  R C Matthews; J P Burnie; S Tabaqchali
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

3.  Candidiasis in the transplant patient.

Authors:  R A Clift
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

4.  Hormonal factors in vaginal candidiasis in rats.

Authors:  O S Kinsman; A E Collard
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

5.  Evidence for a correlation between proteinase secretion and vulvovaginal candidosis.

Authors:  A Cassone; F De Bernardis; F Mondello; T Ceddia; L Agatensi
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

6.  Quantification of vaginal Candida albicans infections in rodents.

Authors:  J F Ryley; S McGregor
Journal:  J Med Vet Mycol       Date:  1986-12

7.  Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans.

Authors:  R C Matthews; J P Burnie; S Tabaqchali
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

8.  Recurrent vulvovaginal candidiasis: vaginal epithelial cell susceptibility to Candida albicans adherence.

Authors:  D J Trumbore; J D Sobel
Journal:  Obstet Gynecol       Date:  1986-06       Impact factor: 7.661

9.  Experimental chronic vaginal candidosis in rats.

Authors:  J D Sobel; G Muller; J F McCormick
Journal:  Sabouraudia       Date:  1985-06

10.  A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors.

Authors:  S S Witkin; J Hirsch; W J Ledger
Journal:  Am J Obstet Gynecol       Date:  1986-10       Impact factor: 8.661

View more
  66 in total

1.  What to do with the patient with recurrent vulvovaginal candidiasis.

Authors:  J S Bingham
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Vulvar Vestibulitis Syndrome: A Post-infectious Entity?

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

3.  Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.

Authors:  F L Wormley; J Chaiban; P L Fidel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Effects of reproductive hormones on experimental vaginal candidiasis.

Authors:  P L Fidel; J Cutright; C Steele
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 5.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

6.  Mucosal Candida infection and colonisation as well as associated risk factors in solid organ transplant recipients.

Authors:  L Antoniewicz; D Relijc; C Poitschek; E Presterl; A Geusau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-02       Impact factor: 3.267

7.  Genetic basis for recurrent vulvo-vaginal candidiasis.

Authors:  Martin Jaeger; Theo S Plantinga; Leo A B Joosten; Bart-Jan Kullberg; Mihai G Netea
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

Review 8.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 10.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.